Top Buy Stocks
Sign In
Invest in CERS
$1.33
+0.0400 (+3.10%)
At Close: May 16, 2025
Cerus Earnings Calls
Q1 2025
Beat
-$0.0400 (20.00%)
| Release date | May 01, 2025 |
| EPS estimate | -$0.0500 |
| EPS actual | -$0.0400 |
| EPS Surprise | 20.00% |
| Revenue estimate | 47.442M |
| Revenue actual | 43.239M |
| Revenue Surprise | -8.86% |
Q4 2024
| Release date | Feb 20, 2025 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.0100 |
| Revenue estimate | 52.953M |
| Revenue actual | 50.809M |
| Revenue Surprise | -4.05% |
Q3 2024
Missed
-$0.0200 (-33.33%)
| Release date | Oct 30, 2024 |
| EPS estimate | -$0.0150 |
| EPS actual | -$0.0200 |
| EPS Surprise | -33.33% |
| Revenue estimate | 50.687M |
| Revenue actual | 46.017M |
| Revenue Surprise | -9.21% |
Q2 2024
Missed
-$0.0300 (-25.00%)
| Release date | Aug 01, 2024 |
| EPS estimate | -$0.0240 |
| EPS actual | -$0.0300 |
| EPS Surprise | -25.00% |
| Revenue estimate | 46.63M |
| Revenue actual | 45.079M |
| Revenue Surprise | -3.33% |
Last 4 Quarters for Cerus
Below you can see how CERS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q2 2024
Missed
| Release date | Aug 01, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $2.04 |
| EPS estimate | -$0.0240 |
| EPS actual | -$0.0300 |
| EPS surprise | -25.00% |
| Date | Price |
|---|---|
| Jul 26, 2024 | $2.38 |
| Jul 29, 2024 | $2.30 |
| Jul 30, 2024 | $2.28 |
| Jul 31, 2024 | $2.26 |
| Aug 01, 2024 | $2.04 |
| Aug 02, 2024 | $2.35 |
| Aug 05, 2024 | $2.22 |
| Aug 06, 2024 | $2.19 |
| Aug 07, 2024 | $2.09 |
| 4 days before | -14.29% |
| 4 days after | 2.45% |
| On release day | 15.20% |
| Change in period | -12.18% |
Q3 2024
Missed
| Release date | Oct 30, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $1.72 |
| EPS estimate | -$0.0150 |
| EPS actual | -$0.0200 |
| EPS surprise | -33.33% |
| Date | Price |
|---|---|
| Oct 24, 2024 | $1.63 |
| Oct 25, 2024 | $1.67 |
| Oct 28, 2024 | $1.72 |
| Oct 29, 2024 | $1.70 |
| Oct 30, 2024 | $1.72 |
| Oct 31, 2024 | $1.57 |
| Nov 01, 2024 | $1.52 |
| Nov 04, 2024 | $1.56 |
| Nov 05, 2024 | $1.66 |
| 4 days before | 5.52% |
| 4 days after | -3.49% |
| On release day | -8.72% |
| Change in period | 1.84% |
Q4 2024
| Release date | Feb 20, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $1.74 |
| EPS estimate | -$0.0100 |
| EPS actual | -$0.0100 |
| Date | Price |
|---|---|
| Feb 13, 2025 | $1.80 |
| Feb 14, 2025 | $1.85 |
| Feb 18, 2025 | $1.86 |
| Feb 19, 2025 | $1.81 |
| Feb 20, 2025 | $1.74 |
| Feb 21, 2025 | $1.65 |
| Feb 24, 2025 | $1.64 |
| Feb 25, 2025 | $1.63 |
| Feb 26, 2025 | $1.64 |
| 4 days before | -3.33% |
| 4 days after | -5.75% |
| On release day | -5.17% |
| Change in period | -8.89% |
Q1 2025
Beat
| Release date | May 01, 2025 |
| Fiscal end date | Mar 31, 2025 |
| Price on release | $1.30 |
| EPS estimate | -$0.0500 |
| EPS actual | -$0.0400 |
| EPS surprise | 20.00% |
| Date | Price |
|---|---|
| Apr 25, 2025 | $1.35 |
| Apr 28, 2025 | $1.34 |
| Apr 29, 2025 | $1.36 |
| Apr 30, 2025 | $1.32 |
| May 01, 2025 | $1.30 |
| May 02, 2025 | $1.35 |
| May 05, 2025 | $1.30 |
| May 06, 2025 | $1.25 |
| May 07, 2025 | $1.30 |
| 4 days before | -3.70% |
| 4 days after | 0% |
| On release day | 3.85% |
| Change in period | -3.70% |
Cerus Earnings Call Transcript Summary of Q1 2025
Cerus Corporation Q1 2025 Earnings Call Summary for Investors:
1. Strong Financial Performance:
- Q1 2025 product revenue reached $43.2 million, a 13% increase year-over-year.
- North American platelet sales grew by 22%, driving significant revenue growth.
- Full-year product revenue guidance maintained at $194 million to $200 million, including expected revenue contributions from Integrated Fresh Component (IFC) of $12 million to $15 million.
2. Operational Highlights:
- Cerus has established a strong foundation in transfusion medicine with approximately 20 million INTERCEPT units treated globally, utilized in over 40 countries.
- The company received CE Mark approval for the INT200, an LED-based illumination device, earlier than expected, anticipated to enhance operational efficiency for blood centers.
3. Expansion and Product Development:
- Continued development of the INTERCEPT red blood cell program with an updated CE Mark application submitted in April.
- Phase 3 clinical study (RedeS) for US market has enrolled over 500 patients, with completion expected by H2 2025.
4. Growth Prospects:
- Significant interest in expansion into new geographies, including Saudi Arabia and Germany, with the INT200 seen as pivotal for gaining traction.
- Positive customer feedback on the new technology reinforces the value proposition of Cerus’ offerings.
5. Financial Outlook and Strategy:
- The company aims for positive operating cash flow and continued positive non-GAAP adjusted EBITDA for 2025.
- Operating expenses increased to $36.9 million due to investments tied to R&D, government contracts, and staffing adjustments; however, profit margins remain stable.
6. Tariff Implications:
- Current tariffs may modestly impact gross margins, but expectations remain above 50%.
- Cerus is not forecasting significant new investments that would adversely affect adjusted EBITDA beyond operational adjustments.
7. Customer Demand and Supply Chain:
- Anticipated increase in supply of IFC products to meet growing hospital demand, bolstered by new manufacturing capabilities and production partnerships.
- Stable back-end supply chain management is set to enhance product availability and efficiency.
Overall, Cerus Corporation is positioned favorably for growth through innovative product launches and an expanding market presence while maintaining a strong financial outlook and commitment to improving blood safety standards. Investors should monitor updates on regulatory approvals and product performance in the upcoming quarters.
Cerus Earnings History
Earnings Calendar
FAQ
When is the earnings report for CERS?
Cerus Corporation (CERS) has scheduled its earnings report for Aug 07, 2025 after the markets close.
What is the CERS price-to-earnings (P/E) ratio?
CERS P/E ratio as of May 16, 2025 (TTM) is -12.34.
What is the CERS EPS forecast?
The forecasted EPS (Earnings Per Share) for Cerus Corporation (CERS) for the first fiscal quarter 2025 is -$0.0400.
What are Cerus Corporation's retained earnings?
On its balance sheet, Cerus Corporation reported retained earnings of $43.24 million for the latest quarter ending Mar 31, 2025.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
